Highest-materiality recent filing
Bio-Rad Q1 GAAP net loss $527M ($19.55/share); net sales +1.1% to $592.1M
Net sales $592.1M, up 1.1% YoY; GAAP gross margin 52.3% (flat YoY), non-GAAP gross margin 53.1%.
Bio-Rad Q4 GAAP operating loss $118.9M; non-GAAP EPS down to $2.51 from $2.90
Q4 GAAP operating loss $118.9M vs income $58.4M YoY; gross margin down 140bps to 49.8%.
Bio-Rad posts GAAP net loss of $342M in Q3 2025; non-GAAP EPS rises to $2.26
Revenue $653.0M, up slightly from $649.7M year-over-year.
Bio-Rad Q2 revenue up 2% to $652M; completes Stilla acquisition
Q2 2025 revenue $651.6M (+2.1% YoY); GAAP net income $317.8M vs loss $2,165.5M (prior year included Sartorius losses).
Bio-Rad Q1 revenue falls 4% to $585M; full-year 2025 outlook moderated on uncertainty
Revenue $585.4M, down from $610.8M YoY; GAAP gross margin 52.3% vs 53.4%.
Bio-Rad Q4 revenue down 2%; launches restructuring (5% workforce cut) and offers to acquire Stilla
Q4 2024 revenue $667.5M vs $681.2M YoY; GAAP operating income $58.4M vs $95.3M.
Bio-Rad Q3 revenue up 2.8% to $649.7M; net income $653.2M on Sartorius gain
Net sales $649.7M, +2.8% YoY; currency-neutral +3.4%; Clinical Diagnostics grew 5.6% to $388.8M.
Bio-Rad appoints Jon DiVincenzo as President and COO, replacing retiring Andy Last
DiVincenzo joins from Labcorp, where he was EVP and President, Central Laboratories & International.
Bio-Rad Q2 net sales down 6.3% YoY; Life Science weak, Diagnostics up 2.1%; board adds $500M buyback
Q2 net sales $638.5M, -6.3% YoY; Life Science $250.5M (-16.5%), Diagnostics $387.9M (+2.1%).
Bio-Rad Q1 net sales down 9.8% to $610.8M; Life Science segment falls 25.3% YoY
Net sales $610.8M, down 9.8% YoY (currency-neutral -9.6%); operating income $44.7M vs $61.9M.
On August 20, 2024, Bio-Rad Laboratories, Inc. (the “Company”) announced the appointment by the Board of Directors of the Company of Jonathan P. DiVincenzo as the Company’s President and Chief Operating Officer (including as principal operating officer), effective September 9, 2024.
Dr. Last will be retiring from his position on September 5, 2024.
Effective on Mr. DiVincenzo’s September 9, 2024 start date as the Company’s President and Chief Operating Officer, Norman Schwartz will continue as the Company’s Chief Executive Officer and Chairman of the Board and will no longer be the Company’s President.
On April 26, 2024, the Company disclosed that Roop K. Lakkaraju, the Company’s Executive Vice President and Chief Financial Officer (and principal financial officer) will act as the Company’s principal accounting officer.
On April 22, 2024, Simon May, the Executive Vice President and President, Life Science Group, of Bio-Rad Laboratories, Inc. (the “Company”) and a named executive officer of the Company, notified the Company of his plans to resign from the Company to pursue another opportunity, effective as of May 1, 2024.
On April 24, 2024, James J. Barry, currently the Company’s Senior Vice President of Global Manufacturing, was appointed to the position of Executive Vice President and President, Life Science Group, effective May 1, 2024.
Max materiality 0.80 · Median 0.57 · Most common event earnings